Blake Borgeson Sells 30,000 Shares of Recursion Pharmaceuticals (NASDAQ:RXRX) Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 30,000 shares of the stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $3.52, for a total transaction of $105,600.00. Following the transaction, the director directly owned 6,199,863 shares in the company, valued at $21,823,517.76. This trade represents a 0.48% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, April 7th, Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $3.10, for a total transaction of $93,000.00.

Recursion Pharmaceuticals Stock Down 4.7%

Shares of RXRX stock traded down $0.16 on Thursday, reaching $3.27. 11,967,164 shares of the company were exchanged, compared to its average volume of 16,680,465. The company has a market cap of $1.72 billion, a price-to-earnings ratio of -2.21 and a beta of 1.05. The company has a 50-day moving average of $3.40 and a 200-day moving average of $4.13. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.50 and a quick ratio of 5.50. Recursion Pharmaceuticals, Inc. has a one year low of $2.80 and a one year high of $7.18.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.08. Recursion Pharmaceuticals had a negative net margin of 863.37% and a negative return on equity of 63.98%. The company had revenue of $6.47 million for the quarter, compared to analyst estimates of $15.78 million. During the same quarter in the prior year, the business posted ($0.50) EPS. The firm’s revenue was down 56.8% compared to the same quarter last year. Analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.08 earnings per share for the current year.

Wall Street Analysts Forecast Growth

RXRX has been the subject of several analyst reports. Bank of America decreased their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating for the company in a research note on Wednesday, February 25th. Wall Street Zen lowered shares of Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Needham & Company LLC restated a “buy” rating and set a $8.00 price target on shares of Recursion Pharmaceuticals in a research note on Thursday. JPMorgan Chase & Co. cut their price objective on shares of Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating for the company in a report on Thursday, April 30th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Tuesday, April 21st. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $9.20.

Key Stories Impacting Recursion Pharmaceuticals

Here are the key news stories impacting Recursion Pharmaceuticals this week:

• Positive Sentiment: Management highlighted tangible clinical progress across wholly‑owned and partnered programs (REC‑1245, REC‑4881, REC‑4539), including early REC‑1245 safety/PK data and FDA engagement on REC‑4881 — items that support long‑term value creation. Press Release
• Positive Sentiment: Early clinical data for RBM39 degrader REC‑1245 were described as well‑tolerated with dose‑dependent PK and no DLTs to date — an encouraging Phase 1/2 signal that analysts and biotech investors typically reward. Yahoo AI Stock Article
• Positive Sentiment: Analyst support: Needham reaffirmed a Buy and set an $8 price target, implying substantial upside from current levels and providing a catalyst if broader sentiment improves. Benzinga
• Neutral Sentiment: Q1 results and the earnings/strategy call emphasized “signal over noise” and prioritizing proof‑points from AI‑driven programs — a message that supports thesis execution but is not an immediate financial catalyst. Earnings Transcript
• Neutral Sentiment: Insider transaction: Director Blake Borgeson sold 30,000 shares under a pre‑arranged Rule 10b5‑1 plan (small ~0.48% reduction in his holdings), a routine disclosure that appears procedural rather than a red flag. Insider Trades
• Negative Sentiment: Revenue missed expectations materially — Q1 revenue of $6.47M versus ~$15.8M expected, down ~57% year‑over‑year as Roche collaboration income declined; this top‑line deterioration is the primary near‑term driver of the share pullback. MarketBeat Earnings
• Negative Sentiment: Despite an EPS beat (loss of $0.22 vs. consensus ‑$0.30), the company still shows negative margins and returns, and analysts expect continued losses — meaning valuation depends heavily on future trial readouts and partnership revenue recovery. Zacks

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of RXRX. Vanguard Group Inc. grew its position in shares of Recursion Pharmaceuticals by 18.6% during the 4th quarter. Vanguard Group Inc. now owns 47,187,759 shares of the company’s stock valued at $192,998,000 after purchasing an additional 7,407,606 shares in the last quarter. State Street Corp grew its position in shares of Recursion Pharmaceuticals by 38.7% during the 4th quarter. State Street Corp now owns 25,333,888 shares of the company’s stock valued at $103,616,000 after purchasing an additional 7,064,963 shares in the last quarter. Norges Bank purchased a new position in shares of Recursion Pharmaceuticals during the 4th quarter valued at $23,473,000. ARK Investment Management LLC grew its position in shares of Recursion Pharmaceuticals by 11.2% during the 4th quarter. ARK Investment Management LLC now owns 37,316,856 shares of the company’s stock valued at $152,626,000 after purchasing an additional 3,771,357 shares in the last quarter. Finally, Millennium Management LLC purchased a new position in shares of Recursion Pharmaceuticals during the 4th quarter valued at $6,118,000. 89.06% of the stock is owned by institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.